The requirement of CD4+ T cells for recall response (Fig. 1g) and the requirement of Bcl-6 expression in late-stage CD4+ T cells for prolonged survival (Fig. 4j) prompted us to ask if M002 treatment had the potential to increase the memory feature of CD4+ T cells in the tumor. Here, BCL6 is linked to neoplasm.